Back
Corporate News
Biocon Malaysia receives EMA approval for new drug product fill finish line for Semglee'
16-Jul-2026, 09:34
Biocon has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee' (insulin glargine) at its insulin manufacturing facility in Malaysia.
Biocon has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee' (insulin glargine) at its insulin manufacturing facility in Malaysia.
Supplies to Europe from this line are expected to begin from Q2FY27.